NYSE:HAE - Haemonetics Stock Price, Forecast & News

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings results on Tuesday, February, 4th. The medical instruments supplier reported $0.94 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.76 by $0.18. The medical instruments supplier earned $259 million during the quarter, compared to the consensus estimate of $255.40 million. Haemonetics had a net margin of 7.98% and a return on equity of 27.78%. Haemonetics's revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 EPS. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Haemonetics.

Haemonetics issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share (EPS) guidance of 3.30-3.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.18. The company issued revenue guidance of $996.606M - 1.016 billion, compared to the consensus revenue estimate of $1 billion.

6 equities research analysts have issued 1-year target prices for Haemonetics' shares. Their forecasts range from $140.00 to $150.00. On average, they anticipate Haemonetics' stock price to reach $144.33 in the next year. This suggests a possible upside of 19.9% from the stock's current price. View Analyst Price Targets for Haemonetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

Headlines about HAE stock have trended extremely negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Haemonetics earned a news impact score of -5.0 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Haemonetics.

Haemonetics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,270,000 shares, an increase of 25.7% from the January 15th total of 1,010,000 shares. Based on an average daily trading volume, of 346,200 shares, the short-interest ratio is currently 3.7 days. Currently, 2.5% of the company's stock are short sold. View Haemonetics' Current Options Chain.

Some companies that are related to Haemonetics include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Antares Pharma (ATRS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Apache (APA), Zoetis (ZTS), NVIDIA (NVDA), Pfizer (PFE), Micron Technology (MU), Nexstar Media Group (NXST) and Citigroup (C).

Haemonetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (5.36%), Renaissance Technologies LLC (4.85%), FMR LLC (4.22%), Jackson Square Partners LLC (3.54%), State Street Corp (3.26%) and Franklin Resources Inc. (2.03%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, AQR Capital Management LLC, Man Group plc, Eagle Asset Management Inc., PNC Financial Services Group Inc., Russell Investments Group Ltd., Castleark Management LLC and State of Tennessee Treasury Department. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Capital Research Global Investors, Westfield Capital Management Co. LP, Credit Suisse AG, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Jackson Square Partners LLC and UBS Group AG. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $120.38.

Haemonetics has a market capitalization of $6.05 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]